Machine learning outperformed conventional pharmacokinetic models for predicting initial vancomycin serum concentrations in septic patients, according to a retrospective intensive care study. The work suggests that data-driven dosing support could reduce the guesswork that contributes to under- or over-exposure early in treatment. Separately, another review-level item links personalized fluid resuscitation to reduced 30-day sepsis mortality, contrasting individualized approaches with fixed-volume administration. The combined message from these reports is that sepsis management may increasingly benefit from patient-specific decision support rather than one-size protocols. Together, the studies emphasize rapid, bedside-relevant optimization: vancomycin timing and targeting and fluid strategy choices can both swing early outcomes. While both items rely on non-interventional designs, their direction supports ongoing interest in “precision” critical care workflows. For biotech and clinical stakeholders, these findings point to opportunities for digital biomarkers and clinical models that can be integrated into pharmacy and ICU dosing protocols to improve consistency and outcomes.